Drug Type Small molecule drug |
Synonyms- |
Target |
Mechanism IKKε inhibitors(inhibitor of nuclear factor kappa B kinase subunit epsilon inhibitors), TBK1 inhibitors(Serine/threonine-protein kinase TBK1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Elgia Therapeutics, Inc.Startup |
Active Organization Elgia Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Atherosclerosis | Preclinical | US | Elgia Therapeutics, Inc.Startup | 12 Jul 2024 |
Fibrosis, Liver | Preclinical | US | Elgia Therapeutics, Inc.Startup | 12 Jul 2024 |
Inflammatory Bowel Diseases | Preclinical | US | Elgia Therapeutics, Inc.Startup | 12 Jul 2024 |